Index
Module 2 • Research Methods
Research Design, Biostatistics & Literature Evaluation
9%
Learning Objectives
Research Design, Biostatistics & Literature Evaluation
Julie E. Farrar ~3 min read Module 2 of 20
3
/ 32

Research Design, Biostatistics, and Literature Evaluation

Learning Objectives

1

Identify factors influencing the conduct of essential

critical care research.

2Evaluate the appropriateness of various statistical

tests for a set of data.

3

Apply concepts of research design and analysis to

clinical care.

Abbreviations in This Chapter

4F-PCC Four-factor prothrombin complex concentrate

ARDSAcute respiratory distress syndrome
ARRAbsolute risk reduction

CI

Confidence interval

CRP

C-reactive protein

ICU

Intensive care unit

IRB

Institutional review board

NMBANeuromuscular blocking agent

NPV

Negative predictive value

OR

Odds ratio

PPV

Positive predictive value

QI

Quality improvement

RR

Relative risk

RRRRelative risk reduction

Self-Assessment Questions

Answers and explanations to these questions may be

found at the end of this chapter.

1

Investigators are planning a clinical trial to

determine the optimal resuscitation fluid for trauma

patients. This study will seek to determine whether

administering crystalloid fluid, such as lactated

Ringer solution, or a transfusion strategy involving

packed red blood cells in the trauma field improves

survival to hospital discharge. The investigator

team has consulted with various ethics scholars to

identify relevant issues to be addressed in the trial

design. Which issue is most relevant to the ethical

conduct of this study?

A.Treatment blinding.
B.Uninformative or niche study population.
C.Consent obtained from injured subjects.
D.Design as a noninferiority trial.
2The investigators of a new study are seeking to

identify the optimal end point and study population

to test the effectiveness of a novel drug compound

for septic shock. The novel drug compound is a

recombinant protein that mediates the inflammatory

cascade of sepsis and has had impressive results for

all etiologies of septic shock in preclinical animal

studies. Historical estimates of septic shock mortal-

ity are 35%โ€“40% in previous studies from the past

10 years; this guides the investigators to calculate

a required sample size of ~800 patients to achieve

80% power. A more recent study of septic shock

reported 28-day mortality to be 20% in the standard

treatment arm. Which best describes the rationale

for selecting a study population or primary end

point?

A.The study should limit inclusion to patients

without a high level of comorbid conditions at

baseline to limit confounders.

B.The study should expand the target population

to include patients with sepsis, not just septic

shock, to show a 28-day mortality benefit.

C.The sample size of the new study will need to

be larger than earlier studies to increase likeli-

hood of obtaining power.

D.The study should limit study inclusion to

patients with septic shock caused by pneumo-

nia to test a relevant study population.

3

A quality improvement (QI) initiative is imple-

mented to improve antimicrobial dosing for patients

with septic shock presenting to the emergency

department. As the pharmacy representative, you

have worked with the pharmacy operations team to

ensure that an appropriate selection of antimicrobial

agents and doses is available in the automated drug-

dispensing machines. Which factor will be most

important in showing the effectiveness of this QI

initiative?

A.Obtaining informed consent for participation in

the QI initiative.

B.Identifying patients with septic shock in triage.
C.Creating a community advertising campaign to

bring awareness to the initiative.

D.Determining the social value of the QI initiative.
HD Video Explanation โ€” Synchronized with PDF
Starts at: minute 2 Open on YouTube